iTeos Therapeutics, Inc.
General ticker "ITOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $432.3M (TTM average)
iTeos Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -18.5%.
Estimated limits based on current volatility of 4.2%: low 7.01$, high 7.63$
Factors to consider:
- Earnings expected soon, date: 2025-05-09 bmo
- US accounted for 0.0% of revenue in the fiscal year ended 2024-12-31
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.12$, 10.47$]
- 2025-12-31 to 2026-12-31 estimated range: [3.96$, 9.72$]
Financial Metrics affecting the ITOS estimates:
- Negative: Non-GAAP EPS, $ of -3.31 <= 0.04
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -23.39 <= 1.79
- Negative: negative Operating income
- Negative: Industry earnings per price (median), % of -27.42 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share, $ of 0 <= 0
- Negative: Shareholder equity ratio, % of 85.93 > 63.75
Short-term ITOS quotes
Long-term ITOS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $267.63MM | $12.60MM | $35.00MM |
| Operating Expenses | $141.31MM | $163.70MM | $194.53MM |
| Operating Income | $126.32MM | $-151.10MM | $-159.53MM |
| Non-Operating Income | $22.41MM | $42.07MM | $39.19MM |
| R&D Expense | $97.36MM | $113.30MM | $145.45MM |
| Income(Loss) | $148.74MM | $-109.03MM | $-120.34MM |
| Taxes | $52.08MM | $3.61MM | $14.07MM |
| Profit(Loss)* | $96.65MM | $-112.64MM | $-134.41MM |
| Stockholders Equity | $663.33MM | $575.23MM | $590.29MM |
| Assets | $754.99MM | $667.59MM | $686.98MM |
| Operating Cash Flow | $-111.19MM | $-103.76MM | $-98.18MM |
| Capital expenditure | $0.94MM | $2.97MM | $1.63MM |
| Investing Cash Flow | $-446.06MM | $72.66MM | $-131.15MM |
| Financing Cash Flow | $1.98MM | $1.11MM | $122.24MM |
| Earnings Per Share** | $2.72 | $-3.15 | $-3.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.